There is a small inverse association between plasma omega-6 and omega-3 polyunsaturated fatty acids (PUFAs) and cancer, according to a study published online Oc ...

Postintervention and 3-month follow-up assessments were evaluated to determine the feasibility and effectiveness of GET in managing distress in young Latino men with testicular cancer.

High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.

The United States launched the most new cancer drugs during the study period (n=345). Other countries with a high number of launches were Japan (n=224), Canada (n=221), Australia (n=204), the United ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...

A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

Most people erroneously think pancreatic cancer occurs only in older people and that they cannot alter risk. HealthDay News — Most people continue to believe that pancreatic cancer affects only the ...

With a median follow-up duration of 55 months, the tandem ASCT group had a median PFS of 42 months compared with 62 months in the single ASCT group. In a real-world study involving patients with ...

Lack of insurance accounts for significant proportion of racial, ethnic disparities in stage III to IV diagnoses across range of cancers.